DarwinHealth is a precision-focused cancer medicine company, utilising systems-biology derived algorithms to identify appropriate therapies for cancer patients and to systematically discover and prioritize the next generation of immunogenic, tumor-specific antigens.
Under the terms of the agreement, DarwinHealth will utilize a combined single-cell transcriptome analysis and bioinformatics-based approach using both mouse and human cancerous and non-cancerous tissues to identify the next generation of shared "off-the-shelf" tumor-specific antigens.
Hookipa will perform the validation experiments and be granted exclusive rights to the development, manufacturing and commercialization of products arising from the collaboration.
Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immuno-therapeutics targeting infectious diseases and cancers based on its proprietary technology platform that is designed to reprogram the body's immune system.
Its proprietary arenavirus-based technologies, Vaxwave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce potent antigen specific CD8+ T cells and pathogen-neutralizing antibodies.
Both, Vaxwave and TheraT, are designed to allow for repeat administration while maintaining an immune response.
TheraT has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. Our "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.
The company has successfully completed a Phase 1 trial of a Vaxwave-based prophylactic vaccine to protect against cytomegalovirus infections. It has initiated enrollment for a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
To expand its infectious disease portfolio, the company as forged a partnership with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. The company is building a proprietary immuno-oncology pipeline by targeting TheraT towards virally mediated cancer antigens, self-antigens and next-generation antigens.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results